---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000229"
form_type: "8-K/A"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-11-27T23:59:59+00:00"
generated_at: "2026-05-29T14:15:31.340844+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Recursion completes Exscientia acquisition; pro forma shows increased net losses

## Summary
- Total purchase price ~$635.9M; transaction closed Nov 20, 2024.
- Pro forma 2023 net loss of $548.7M ($1.74/share) vs Recursion standalone $328.1M.
- Pro forma 9M 2024 net loss of $476.5M ($1.32/share) vs Recursion standalone $284.8M.
- Combined total assets ~$1.55B, equity ~$1.14B as of Sept 30, 2024.
- Goodwill of $76.9M and intangible assets of $355.1M recorded.

## SEC filing metadata
- accession: 0001601830-24-000229
- form_type: 8-K/A
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-11-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000229/0001601830-24-000229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000229/rxrx-20241119.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000229
- JSON: https://secwatch.observer/filing/0001601830-24-000229.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000229.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.